# Certara

its Simcyp Simulator, a PBPK platform built over 25 years with a consortium of more than 35 pharmaceutical companies, released Version 25 in early 2026 building on EMA qualification, and Certara reported that Simcyp simulation results replaced ten human trials for the chronic myeloid leukemia therapy asciminib.

Source: https://en.bioecon.ru/companies/certara/
Updated: 2026-07-20

- Country: United States
- Ticker: CERT

## Technologies

- [Multi-jurisdictional bio-compliance (FDA+EMA+NMPA+PMDA)](https://en.bioecon.ru/technology/multi-jurisdictional-bio-compliance/)
- [Patient digital twins & in-silico trials](https://en.bioecon.ru/technology/patient-digital-twins-in-silico-trials/)
- [Toxics screening (toxicomics, service)](https://en.bioecon.ru/technology/toxics-screening-toxicomics-service/)